Learn from experts how to monitor and manage ocular toxicities with antibody–drug conjugates.
Download this slideset based on the content from a live satellite symposium with an overview of how treatment with antibody–drug conjugates can cause ocular toxicity for patients with cancer.
Download this slideset based on the content from a live satellite symposium with a case study of the antibody–drug conjugate belantamab mafodotin and the potential for ocular toxicity while receiving this treatment for myeloma.
Download this slideset based on the content from a live satellite symposium on how to best manage ocular toxicity resulting from therapy with antibody–drug conjugates for patients with cancer.
Gain key clinical insights fast, with this short slideset from CCO on key considerations for recognizing and managing ocular toxicities associated with antibody–drug conjugates.
In this on-demand webcast, Asim V. Farooq, MD; Joann Kang, MD; and Paul G. Richardson, MD, review the pathophysiology of ocular toxicities caused by antibody–drug conjugates used to treat cancer and provide guidelines on monitoring and managing these toxicities.
Download this summary resource for a quick guide on identifying and managing ocular toxicities associated with FDA-approved antibody-drug conjugates for patients with cancer.